Jeffrey D. Capello, a director at Neogen Corp., reported a transaction involving 1,776 shares of the company in a recent SEC filing. This filing, dated October 30, 2026, is significant as it underscores Capello's active role in the company and his investment strategy.

Background

Neogen Corp, identified under the SEC Central Index Key 0000711377, operates in the life sciences sector, specifically in the in vitro and in vivo diagnostic substances industry. The company is incorporated in Michigan and has its fiscal year ending on May 31. Neogen has been a key player in the diagnostics market, focusing on health and safety solutions.

What the Filing Says

The SEC filing reveals that on October 29, 2026, Capello acquired 1,776 shares of Neogen's common stock at a price of $12.21 per share. Following this transaction, Capello owns a total of 42,892 shares of Neogen. The filing states, "Each RSU is the economic equivalent of one share of common stock. On October 29, 2026, these RSUs vested and were settled for an equal number of shares of common stock." This transaction indicates Capello's commitment to the company and its future.

Impact

This transaction may affect Neogen's shareholders and investors, as it reflects the confidence of its directors in the company’s performance and prospects. As a director, Capello's actions can influence investor sentiment and market perception of Neogen's stability and growth potential.

What's Next

The filing does not say what happens next.